#bcsm search results
WATCH: @stolaney1 discusses how the shifting understanding of HER2 expression in breast cancer may affect the management of this disease. @DanaFarber @harvardmed #bcsm #oncology onclive.com/view/dr-tolane…
Phase II Clinical Study of Adebrelimab and Bevacizumab Combined With Cisplatin/Carboplatin in Patients With Triple-Negative Breast Cancer With Brain Metastases (ABC Study). Read the full article. ascopubs.org/doi/abs/10.120… #bcsm #BreastCancer #btsm
Breast cancer patients with metastases face significant sexual concerns. A couple-based videoconference sexual QOL intervention shows benefit for patients' and partners' sexual and psychosocial outcomes. acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn… @DrJennyReese @OncoAlert #BCSM
Implementing a Multicomponent Navigation Program to Reduce Time Intervals to Treatment Initiation for Advanced Breast Cancer in Paraguay. Read the full article. bit.ly/41Ya9CU #BreastCancer #bcsm
Survival Outcomes With or Without Risk-Reducing Mastectomy in BRCA1 and BRCA2 Pathogenic Variant Carriers. Read the full article. brnw.ch/21x07Pg #BreastCancer #bcsm
How is the HR+, HER2– MBC treatment landscape evolving? Join Aditya Bardia, MD (UCLA), as he discusses: 🔹 Endocrine therapy today 🔹 Unmet needs in MBC 🔹 ESR1 mutations & resistance Register here: e.lilly/4cUQlFF #MBC #BCSM #ESR1m
This prospective study analyzed 27 different PGS in 3.620 women w/ BC. The model performance for #CVD risk prediction was not statistically sig. This highlights the need for new PGS models specifically for cancer pts. jacc.org/doi/10.1016/j.… #JACCCardioOnc #BCsm @fiorica_peter
Rise and Fall of Neoadjuvant Carboplatin for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer. Co-authored by @PTarantinoMD. Read the full article. brnw.ch/21wZPaf #BreastCancer #bcsm
Windows of Opportunity in Breast Cancer: Learning More From Fewer Patients in a Shorter Time. Read the full article. brnw.ch/21wZRmX #BreastCancer #bcsm
#bcsm March 3rd is ##TNBCAwarenessDay & for those of us living with metastatic TNBC, awareness must mean action. Brain metastases remain one of the most urgent unmet needs in mTNBC. As a rare long-term 🦄 (~10 yrs) dx w/ mTNBC, I’m proud to serve on the @metavivor Board & support
Congratulations to @AdrianaKahnMD, recipient of a @metavivor Early Career Investigator Award for “BERLIN: A Phase II Study of Sacituzumab Tirumotecan in Metastatic Triple-Negative Breast Cancer with Active Brain Metastases,” a promising antibody-drug conjugate for patients with
One last appeal to fund metastatic breast cancer research through @metavivor. It has been an honor to serve as president of the board of directors this year and I’m energized to continue to lead an amazing team in 2026. #bcsm #research
As the year comes to a close, we are still working to raise critical funds to support #metastaticbreastcancer research, advocacy, and patient programs. Every gift, no matter the size, helps move this work forward. Give to #METAvivor today: metavivor.org/events-campaig…
Tumor biology in #BreastCancer is important, but anatomic extent of disease still has a role in determining prognosis. A recent study from @JenniferPlichta and @DukeSurgery investigators explains more: acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn… @OncoAlert @DukeCancer CC: @oreganruth #BCSM
I hope such data do not suppress the enthusiasm about PO SERDs being good drugs, changing the landscape of HR+ breast cancer. The "Strategy" of SERENA6 is good science to build upon, but its implementation in practice today is not justified IMO. @OncoAlert #bcsm @OncBrothers
Very important data. Even in the absence of oral SERD at crossover, there is no apparent OS benefit as yet for switch based on molecular ESR1mut detection without radiological progression. And in current practice, all patients would get an oral SERD at radiological/clinical PD
Single-dye sentinel lymph node biopsy after neoadjuvant therapy in patients initially diagnosed with cN1 #BreastCancer yielded a clinically acceptable false-negative rate. acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn… @OncoAlert #BCSM
It will be interesting to see the consensus on how to use TDXd + pertuzamab 1st line - how long should induction be, what should be maintenance (likely dependent on ER status, +/- brain mets, and ALWAYS what the patient wants, after true shared decision making discussion) #bcsm
Great news for patients. Now we have to decide how to optimally use this combo! FDA Approves T-DXd Plus Pertuzumab for HER2-Positive Breast Cancer! Maintenance and added value of P are key issues. @OncoAlert targetedonc.com/view/fda-appro…
The Pathologic Response Evaluation and Detection In Circulating Tumor-DNA (PREDICT-DNA) Study: Ultrasensitive ctDNA Assessment of Breast Cancer Minimal Residual Disease. Co-authored by @benhopark. Read the full article. bit.ly/4uWm4yp #bcsm #BreastCancer
Cracks in the Estrogen Carcinogenesis of Breast Cancer. Read the full article. bit.ly/4bqGVRp #BreastCancer #bcsm
TAC-induced vascular dysfunction seen in breast cancer survivors is absent in premenopausal women, likely owing to estrogen-mediated protection against oxidative stress and eNOS inhibition. Get the details: jacc.org/doi/10.1016/j.… #JACC #ACCWIC #BCsm #Menopause #CardioOnc
Shifting Landscape of HER2+ Metastatic Breast Cancer Treatment. Absolute progress for patients. #bcsm @DFCI_BreastOnc
WATCH: @stolaney1 discusses how the early-stage HER2-positive breast cancer treatment paradigm is evolving with the emergence of new phase 3 data. @DanaFarber @harvardmed #bcsm #oncology onclive.com/view/dr-tolane…
WATCH: @stolaney1 discusses how the shifting understanding of HER2 expression in breast cancer may affect the management of this disease. @DanaFarber @harvardmed #bcsm #oncology onclive.com/view/dr-tolane…
How is the HR+, HER2– MBC treatment landscape evolving? Join Aditya Bardia, MD (UCLA), as he discusses: 🔹 Endocrine therapy today 🔹 Unmet needs in MBC 🔹 ESR1 mutations & resistance Register here: e.lilly/4cUQlFF #MBC #BCSM #ESR1m
Implementing a Multicomponent Navigation Program to Reduce Time Intervals to Treatment Initiation for Advanced Breast Cancer in Paraguay. Read the full article. bit.ly/41Ya9CU #BreastCancer #bcsm
#bcsm medpagetoday.com/hematologyonco… Under review, Camizestrant for HR+ #metastaticbreastcancer & Capivasertib for Prostate cancer. “For the first time since last July the FDA's Oncologic Drugs Advisory Committee (ODAC) will meet on Thursday to evaluate two cancer drugs after FDA
WATCH: @MeganKruseMD, breaks down the use of FES-PET/CT in breast cancer management. @ClevelandClinic #bcsm #oncology Read more insights from Dr Kruse on this imaging modality! onclive.com/view/refined-b…
I hope such data do not suppress the enthusiasm about PO SERDs being good drugs, changing the landscape of HR+ breast cancer. The "Strategy" of SERENA6 is good science to build upon, but its implementation in practice today is not justified IMO. @OncoAlert #bcsm @OncBrothers
Very important data. Even in the absence of oral SERD at crossover, there is no apparent OS benefit as yet for switch based on molecular ESR1mut detection without radiological progression. And in current practice, all patients would get an oral SERD at radiological/clinical PD
WATCH: @stolaney1 discusses how the early-stage HER2-positive breast cancer treatment paradigm is evolving with the emergence of new phase 3 data. @DanaFarber @harvardmed #bcsm #oncology onclive.com/view/dr-tolane…
ICYMI: Watch @SaraNunneryMD, and @Neil_Iyengar, discuss the integration of GLP-1 agonists into breast cancer management. @TNOncology @WinshipAtEmory #bcsm #oncology Prefer to listen? Find the audio on your favorite podcast platforms! 🎧 onclive.com/view/evolving-…
Clinical Response to Poly(ADP-ribose) Polymerase Inhibitor in Metastatic Breast Cancer with a Germline Reduced-Penetrance BRCA2 Pathogenic Variant: A Molecular Tumor Board Discussion. Read the full article. bit.ly/4sXxZJO #BreastCancer #bcsm
Molecular Characterization of Patients with Metastatic Invasive Lobular Carcinoma: Using Real-World Data to Describe This Unique Clinical Entity [Sep 10, 2025] Davis et al. @CCR_AACR aacrjournals.org/clincancerres/… #bcsm #PrecisionMedicine #camoldx @TempusAI
![mtmdphd's tweet image. Molecular Characterization of Patients with Metastatic Invasive Lobular Carcinoma: Using Real-World Data to Describe This Unique Clinical Entity [Sep 10, 2025] Davis et al. @CCR_AACR
aacrjournals.org/clincancerres/… #bcsm #PrecisionMedicine #camoldx @TempusAI](https://pbs.twimg.com/media/HHAAwKZbwAIau6J.png)
FT can persist in all aspects of BC survivorship, esp w/ late toxicities. We discuss how and share three demonstrative cases: Abby, Brianna, and Catherine. 🤩MDA PGY-2 @ThatDamDoc and @fumikochino @UTMDAnderson #bcsm #financialtoxicity #radonc doi.org/10.1007/s12609…
Integrating stromal tumor infiltrating lymphocytes into the PREDICT model (PREDICT_sTILs) in early TNBC (n=3698) maintains robust calibration (O/E close to 1) with stable discrimination (AUC around 0.74). annalsofoncology.org/article/S0923-… @OncoAlert #bcsm @Annals_Oncology #BreastCancer
WATCH 👀: @meghanrflanagan of @fredhutch notes takeaways from a multidisciplinary tumor board discussion on how genomic assays can guide treatment decisions for DCIS. See the whole video here ➡️: hubs.li/Q04dFXQT0 #bcsm #oncology
Great to see the results from the #TAKTIC study reported today at @TheLancetOncol. Congrats Seth Wander, @maxwellRlloyd & colleagues! #Ipatasertib #bcsm @MGBResearchNews @MGBCI_BreastOnc @harvardmed AKT-targeted triplet therapy in advanced breast cancer ⬇️ sciencedirect.com/science/articl…
Weekly #BreastCancer Newsletter- My take of last week’s publications from select high-impact journals (April 19 - April 26, 2026). @OncoDailyBreast @oncodaily @OncoAlert #BCSM #BreastCancerResearch #BreastCancer
Looking forward to see the latest OPTIMA trial data from @Veracyte at @ASCO 2026. #ASCO26 #BreastCancer #BCSM #PrecisionMedicine #OncologyData #ClinicalTrials #Genomics #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalOncology #OPTIMATrial
EA1241, led by @jsparano of @MountSinaiNYC, is a companion study for patients who previously took part in either the TAILORx or RxPONDER #BreastCancer trials. Learn more: bit.ly/EA1241 #bcsm
⚛️ At a recent OncLive Scientific Interchange and Workshop, breast cancer experts discussed the nuances of using CDK4/6 inhibitors to treat patients with high-risk hormone receptor–positive, HER2-negative early disease. Full details 👀: hubs.li/Q04dxlBv0 #bcsm #oncology
Congratulations Dr. McClelland on your leadership, mentorship, and most importantly your incredible impact. It has been a privilege to be a tiny part of your journey! #bcsm #radonc
Truly honored to receive the 2026 Compassionate Caregiver Award from amazing @myskcle founder/CEO/#breastcancer warrior Sherri White. Also great reuniting with @cwcheath & our first 2 #NAVAH navigators — Ursula Burnette & Tamika Smith! @DoctorThornton #bcsm #RepresentationMatters
2025 is coming to a close, and one thing is clear: It has been an exceptionally intense year in breast cancer. Clinical trials that have the potential to change practice and defined the year 👇 #bcsm ✨️🎄
Dr. Patricia LoRusso shared encouraging results #ASCO25 of a phase I trial for pts with ER+/HER- mBC using a KAT6 inhibitor w fulvestrant, identifying optimal dose to expand to a phase 3 trial. @ASCO @SmilowCancer @OncoAlert #bcsm Abstract 1020 meetings.asco.org/2025-asco-annu…
TAC-induced vascular dysfunction seen in breast cancer survivors is absent in premenopausal women, likely owing to estrogen-mediated protection against oxidative stress and eNOS inhibition. Get the details: jacc.org/doi/10.1016/j.… #JACC #ACCWIC #BCsm #Menopause #CardioOnc
This prospective study analyzed 27 different PGS in 3.620 women w/ BC. The model performance for #CVD risk prediction was not statistically sig. This highlights the need for new PGS models specifically for cancer pts. jacc.org/doi/10.1016/j.… #JACCCardioOnc #BCsm @fiorica_peter
In Black & Hispanic breast & prostate cancer survivors, gamification increased daily steps & physical activity vs attention control, supporting a scalable strategy to reduce CV risk in this population. jacc.org/doi/10.1016/j.… #JACCCardioOnc #SDOH #BCsm #PCsm @ArmenianSaro
PATINA was first presented at #SABCS24 @SABCSSanAntonio and now in @NEJM! This is the SoC for 1L HR+ HER2+ mBC: Anti-HER2 + ET + Palbo after induction chemo. - mPFS 44.3mos vs 29.1mos (HR: 0.74) - #SABC25 Update: At 3yrs, improved CNS progression (or death) w/ Palbo #bcsm
PATINA is now out in @nejm. Among pts with HR+/HER2+ MBC progression-free after chemo induction, adding palbociclib to 1L ET+HER2-blockade maintenance prolonged PFS from 29 mo to an astonishing 44 months (HR 0.75, p=0.02). Congrats @Otto_DFCI & coauthors! nejm.org/doi/full/10.10…
SONIA trial — timing of CDK4/6i in HR+/HER2− MBC: @JAMAOnc ◾ ⬆️ PFS2 modestly with upfront CDK4/6i (31.9 vs 26.7 mo) ◾No OS benefit (47.9 vs 48.1 mo) ◾No delay in chemotherapy or attrition advantage jamanetwork.com/journals/jamao… @OncoAlert #BreastCancer #bcsm
Leptomeningeal disease may no longer be a “therapeutic dead end.” TBCRC049 (phase II): ▪️ OS: 10 months (vs ~4–5 historical) ▪️ LM response: 38% ▪️ Neuro improvement: 58% ➡️ Tucatinib + trastuzumab + capecitabine shows real clinical activity #bcsm #oncology #HER2 @NatureCancer
SERDs are new breast cancer therapies that can cause sinus bradycardia. Using chemical & genetic approaches in zebrafish, Dr. @SANDEEPBASU1, et al. show bradycardia is an on-target effect related to ERα signaling. jacc.org/doi/10.1016/j.… #BCsm #JACCBTS @AartiAsnaniMD @BidmcCvi
The dynamic evolution of HER2 status following neoadjuvant chemotherapy and its prognostic utility highlights the importance of reassessing HER2 status in residual disease in HER2-negative early #BreastCancer. acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn… @OncoAlert #BCSM
Baseline ctDNA demonstrates significant long-term prognostic value in early breast cancer (ABCSG-34). ctDNA persistence during NAT reflects resistance biology, while clearance trends toward improved outcomes. nature.com/articles/s4152… @OncoAlert #BreastCancer #bcsm
🧠 Promising CNS activity in TNBC with active brain metastases with adebrelimab + bevacizumab + cisplatin/carboplatin: ✔ CNS ORR: 77% ✔ Median CNS PFS: 10.3 months ✔ Manageable safety 🔸 Li et al | @JCO_ASCO | #BCSM #brainmets 🔗 ascopost.com/news/april-202…
Adding sTILs to PREDICT (PREDICT_sTILs) refines prognostication in early TNBC, with robust calibration (O/E close to 1) and stable discrimination (AUC around 0.74). annalsofoncology.org/article/S0923-… @OncoAlert #BreastCancer #bcsm @Annals_Oncology
The final webinar in our Post-San Antonio Breast Cancer Symposium (#SABCS) will discuss New Treatment Options for #MetastaticBreastCancer. Join host @maryam_lustberg and @AdrianaKahnMD tonight at 6pm. RSVP: bit.ly/40ffiVM #bcsm @SmilowCancer @YaleMed @YNHH @YaleBreast
Phase II randomized trial: Neoadjuvant palbociclib + ET vs chemotherapy in ER+/HER2− #BreastCancer. Superior Ki-67 suppression ➡️ potent cell-cycle arrest Comparable clinical response, with low pCR in both arms @OncoAlert #bcsm nature.com/articles/s4146…
🎯 Comprehensive blocking of the PI3K/AKT/mTOR pathway: Gedatolisib combinations demonstrate clinically meaningful improvements in PFS in HR+/HER2– advanced #breastcancer. 👩⚕️ Sara A. Hurvitz, MD of @fredhutch | @JCO_ASCO | #BCSM Explore the data ➡️ ascopost.com/news/march-202…
In HR+/HER2− aBC, pts >75 yrs derive greater rwPFS benefit from 1L ET+CDK4/6i vs younger (aHR 0.77), despite worse baseline features yet OS remains inferior (competing risks/attrition). thebreastonline.com/article/S0960-… @OncoAlert #BreastCancer #bcsm
🧬 Phase III PATINA: Palbociclib + anti-HER2 & endocrine therapy improved PFS in HR+/HER2+ mBC after chemo + anti-HER2 📈 Median PFS: 44.3 vs 29.1 mo (HR = 0.75) 💉 Tradeoff: ↑ grade 3–4 AEs: 79.7% vs 30.6% (neutropenia 60.5%) 👨⚕ @Otto_DFCI | #BCSM 🔗 ascopost.com/news/february-…
.@tarasanftmd shares that the use of the Breast Cancer Index #BCI in clinical practice resulted in significant changes in physician recommendations for extended endocrine therapy. #ASCO25 @YaleBreast #bcsm @OncoAlert @SmilowCancer meetings.asco.org/abstracts-pres…
Her2: “From being an oncogenic driver now to a delivery target” for our ADCs @jhaveri_komal! Summary slide from our discussion on testing, target, data in hand, to AEs for Her2 in HR+ mBC! #OncTwitter #bcsm #MedX #MedTwitter @OncoAlert @COR2EDMedEd
Data on TDXd around Ultralow and Low Her2 in HR+ mBC! Discussion of DB06 with @jhaveri_komal : ✅Testing ✅Clinical implications ✅AE management Full🗣️: ⭐️ oncbrothers.com/her2testing-20… ⭐️ cor2ed.com/breast-cancer-… ⭐️ Oncology Brothers podcast #OncTwitter #bcsm @OncoAlert
Something went wrong.
Something went wrong.
United States Trends
- 1. Supreme Court N/A
- 2. Voting Rights Act N/A
- 3. SCOTUS N/A
- 4. Louisiana N/A
- 5. NBA Street N/A
- 6. FOMC N/A
- 7. Comey N/A
- 8. Section 2 N/A
- 9. #HighInfidelityDay N/A
- 10. Deshaun N/A
- 11. #questpit N/A
- 12. Jim Crow N/A
- 13. Garrett Crochet N/A
- 14. #You_Complete_Our_SevEN N/A
- 15. Callais N/A
- 16. Zambia N/A
- 17. Powell N/A
- 18. Sorokin N/A
- 19. Ann Arbor N/A
- 20. Bruce Bowen N/A